Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting [Yahoo! Finance]
Alterity Therapeutics Limited - American Depositary Shares (ATHE)
Company Research
Source: Yahoo! Finance
ATH434 demonstrated clinically meaningful efficacy in modifying disease progression and was well tolerated at both 50 and 75 mg doses MELBOURNE, Australia and SAN FRANCISCO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that data from the ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy (MSA) was presented at the 150 th Annual Meeting of the American Neurological Association (ANA), held in Baltimore, MD. A poster, entitled, “ATH434 Slowed Disease Progression in a Phase 2 Study in Multiple System Atrophy,” was presented by Daniel Claassen, M.D., M.S., Professor of Neurology at Vanderbilt University Medical Center and Coordinating Investigator for the ATH434-201 Phase 2 study. In the study, ATH434 demonstrated clinically meaningful efficacy in modifying dis
Show less
Read more
Impact Snapshot
Event Time:
ATHE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATHE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATHE alerts
High impacting Alterity Therapeutics Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ATHE
News
- Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference [Yahoo! Finance]Yahoo! Finance
- Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual ConferenceGlobeNewswire
- Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System [Yahoo! Finance]Yahoo! Finance
- Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous SystemGlobeNewswire
- Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow ReportGlobeNewswire
ATHE
Sec Filings
- 11/24/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/24/25 - Form 6-K
- ATHE's page on the SEC website